当前位置：
X-MOL 学术
›
Eur. J. Heart Fail.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial
European Journal of Heart Failure ( IF 16.9 ) Pub Date : 2022-07-05 , DOI: 10.1002/ejhf.2608 Michele Senni 1 , Wendimagegn G Alemayehu 2 , David Sim 3 , Frank Edelmann 4 , Javed Butler 5 , Justin Ezekowitz 2 , Adrian F Hernandez 6 , Carolyn S P Lam 3 , Christopher M O'Connor 7 , Burkert Pieske 4 , Piotr Ponikowski 8 , Lothar Roessig 9 , Adriaan A Voors 10 , Cynthia M Westerhout 2 , Ciaran McMullan 11 , Paul W Armstrong 2 ,
European Journal of Heart Failure ( IF 16.9 ) Pub Date : 2022-07-05 , DOI: 10.1002/ejhf.2608 Michele Senni 1 , Wendimagegn G Alemayehu 2 , David Sim 3 , Frank Edelmann 4 , Javed Butler 5 , Justin Ezekowitz 2 , Adrian F Hernandez 6 , Carolyn S P Lam 3 , Christopher M O'Connor 7 , Burkert Pieske 4 , Piotr Ponikowski 8 , Lothar Roessig 9 , Adriaan A Voors 10 , Cynthia M Westerhout 2 , Ciaran McMullan 11 , Paul W Armstrong 2 ,
Affiliation
|
We assessed a subset of the 5040 patients in VICTORIA receiving sacubitril/valsartan, either at randomization (n = 731) or post-randomization drop-in use (n = 425), to evaluate the relationship between the efficacy and safety of combination therapy with vericiguat.
中文翻译：
Vericiguat 对用沙库巴曲/缬沙坦治疗射血分数降低的心力衰竭患者的疗效和安全性：来自 VICTORIA 试验的见解
我们评估了 VICTORIA 接受沙库巴曲/缬沙坦治疗的 5040 名患者的一个子集，无论是在随机分组（n = 731）还是在随机分组后直接使用（n = 425），以评估联合治疗的有效性和安全性之间的关系vericiguat。
更新日期：2022-07-05
中文翻译：
Vericiguat 对用沙库巴曲/缬沙坦治疗射血分数降低的心力衰竭患者的疗效和安全性：来自 VICTORIA 试验的见解
我们评估了 VICTORIA 接受沙库巴曲/缬沙坦治疗的 5040 名患者的一个子集，无论是在随机分组（n = 731）还是在随机分组后直接使用（n = 425），以评估联合治疗的有效性和安全性之间的关系vericiguat。
京公网安备 11010802027423号